PLEASANTON, Calif., Oct. 11 /PRNewswire/ — TriReme Medical, a
leading developer of innovative catheters and stents for the
treatment of complex vascular disease, announced today the closing
of a $17M Round D financing. The financing was led by Bio*One
Capital, a subsidiary of Singapore based EDB Investments (‘EDBI’)
with strong support from current investors, Three Arch Partners and
Adams Street Partners. “We are delighted to have Bio*One join
our group of sophisticated blue chip investors who share our vision
of developing innovative catheter and stent technology for coronary
and peripheral interventional procedures,” said Eitan Konstantino,
Ph.D., President and CEO of TriReme Medical, Inc. “This
investment will allow us to ramp up our commercial activities
worldwide, continue to develop internal R&D programs and pursue
key regulatory approvals for our products in large markets such as
the US, Japan, and China.”
Ms Chu Swee-Yeok, CEO EDBI and Bio*One Capital said, “We are
impressed with the global vision of TriReme’s management team and
its ability to rapidly develop and gain regulatory approvals for
its novel catheter technologies. Its strategy of positioning
itself in Singapore will allow the company to tap on the fast
growing Asian markets and enhance its competitiveness and reach.”
Mark Wan, General Partner at Three Arch Partners added, “This
investment will allow TriReme to maximize the value of its R&D
portfolio by providing for expansion of regulatory approvals and
the creation of a commercial infrastructure that will drive revenue
growth in the coming years.”
About TriReme Medical, Inc.
Based in Pleasanton, California, TriReme Medical, Inc. (TMI) is
a privately held medical device company dedicated to the
development, manufacturing, and commercialization of next
generation percutaneous devices for the treatment of complex
coronary and peripheral arterial disease. The Company’s novel
ballo
‘/>”/>
